Agio Pharmaceuticals Announces Poster Titled 'Improvements In Fatigue And 6-minute Walk Test In Adults With Alpha- Or Beta-non–Transfusion-dependent Thalassemia: The Phase 3 Energize Trial Of Mitapivat'
Portfolio Pulse from Benzinga Newsdesk
Agio Pharmaceuticals has announced a poster presentation titled 'Improvements In Fatigue And 6-minute Walk Test In Adults With Alpha- Or Beta-non–Transfusion-dependent Thalassemia: The Phase 3 Energize Trial Of Mitapivat'.
June 14, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agio Pharmaceuticals has presented positive Phase 3 trial results for Mitapivat, showing significant improvements in fatigue and 6-minute walk test in adults with alpha- or beta-non–transfusion-dependent thalassemia.
The positive results from the Phase 3 Energize trial of Mitapivat are likely to boost investor confidence in Agio Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100